Kawasaki Disease - Pipeline Insight, 2024

This “Kawasaki Disease- Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Kawasaki Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Kawasaki Disease Understanding

Kawasaki Disease: Overview

Kawasaki (Kah-wah-SOCK-ee) Disease, although rare, is the most common cause of acquired (not born with) heart disease in the United States and Japan. More than 80% of the children who get it are younger than 5 years of age. It is more common in boys and in Asians and Asian-Americans. Kawasaki Disease begins suddenly. The disease can cause blood vessels to become inflamed or swollen throughout the body. If untreated, the swelling can lead to damage of the blood vessel walls, especially those that go to the heart (coronary arteries). A section of a blood vessel wall can balloon out and become weak. This is called an aneurysm. Over time, the inflammation in the vessel goes away but the aneurysm stays. Aneurysms can cause serious problems later, most notably blood clots. When treatment begins within 10 days of the start of the disease, there is little risk of blood vessel and heart problems. It is not known what causes the disease. The immune system may be reacting to an unknown virus or there might be a genetic link in families. There is no way to prevent Kawasaki Disease. It is not contagious. It cannot be spread from one person to another. The first sign of Kawasaki Disease is a high fever (over 101°F, and often as high as 104°F) that lasts more than 4 days. Over the next several days (not all at once), these other key signs may occur: The hands and feet get very red and swollen, especially the palms and the soles. Two to three weeks after the start of the fever, the skin on the hands, fingertips and feet usually peels. The inside of the mouth and the lips get red. The lips become dry and cracked, the tongue may have rough, red spots. This is called a “strawberry tongue”, swelling develops in a lymph node on one side of the neck, the eyes become red and look bloodshot. Most children with Kawasaki Disease are also very irritable and fussy. However, not all children have all of these signs. Children may have a milder form, called “incomplete” (atypical) Kawasaki Disease. Both forms can cause damage to blood vessels if not treated right away. There is no single test to know if a child has Kawasaki Disease. The diagnosis is considered when the child has: A high fever for more than 4 days and at least 4 of the key signs. Most children fully recover without any damage to the blood vessels if treatment is started within 10 days.

Kawasaki Disease- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kawasaki Disease pipeline landscape is provided which includes the disease overview and Kawasaki Disease treatment guidelines. The assessment part of the report embraces, in depth Kawasaki Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kawasaki Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Kawasaki Disease R&D. The therapies under development are focused on novel approaches to treat/improve Kawasaki Disease.

Kawasaki Disease Emerging Drugs Chapters

This segment of the Kawasaki Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Kawasaki Disease Emerging Drugs

Ampion: Ampio PharmaceuticalsAmpion is a novel biologic drug containing a blood-derived cyclized peptide and small molecules that target multiple pathways in the innate immune response characteristic of inflammatory disease. These ingredients work together to achieve an anti-inflammatory effect to treat a variety of inflammatory conditions, including osteoarthritis, respiratory illness, and other inflammatory diseases. Research and development for Ampion use in KD is being explored based on preclinical pharmacology studies which show Ampion reduces inflammatory cytokines (e.g., TNFa, IL-1ß) while promoting the production of prostaglandins (e.g., PGE2).

Kawasaki Disease: Therapeutic Assessment

This segment of the report provides insights about the different Kawasaki Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Kawasaki Disease

There are approx. 5+ key companies which are developing the therapies for Kawasaki Disease. The companies which have their Kawasaki Disease drug candidates in the most advanced stage, i.e. Phase I include, Reven Pharmaceuticals.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Kawasaki Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Kawasaki Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Kawasaki Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kawasaki Disease drugs.

Kawasaki Disease Report Insights

• Kawasaki Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Kawasaki Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Kawasaki Disease drugs?
• How many Kawasaki Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Kawasaki Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Kawasaki Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Kawasaki Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ampio Pharmaceuticals
• Anviron
• Reven Pharmaceuticals

Key Products

• Ampion
• ANV120
• RP-OT-1004a

This product will be delivered within 2 business days.